Difference between revisions of "Pancreatic cancer - historical"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "9>" to "9%3E")
m
Line 1: Line 1:
 
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the [http://www.nccn.org/professionals/physician_gls/f_guidelines.asp NCCN Guidelines]. Is there a regimen missing from this list? See the [[Pancreatic_cancer|main pancreatic cancer page]] for current regimens.
 
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the [http://www.nccn.org/professionals/physician_gls/f_guidelines.asp NCCN Guidelines]. Is there a regimen missing from this list? See the [[Pancreatic_cancer|main pancreatic cancer page]] for current regimens.
−
 
 
{| class="wikitable" style="float:right; margin-right: 5px;"
 
{| class="wikitable" style="float:right; margin-right: 5px;"
 
|-
 
|-
Line 6: Line 5:
 
<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]]  |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
 
<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]]  |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
 
|}  
 
|}  
−
 
 
{{TOC limit|limit=3}}
 
{{TOC limit|limit=3}}
−
 
 
=Induction therapy for locally advanced disease, unresectable=
 
=Induction therapy for locally advanced disease, unresectable=
 
==FLEC {{#subobject:a6c123|Regimen=1}}==
 
==FLEC {{#subobject:a6c123|Regimen=1}}==
−
 
 
FLEC: '''<u>F</u>'''luorouracil, '''<u>L</u>'''eucovorin (Folinic acid), '''<u>E</u>'''pirubicin, '''<u>C</u>'''arboplatin
 
FLEC: '''<u>F</u>'''luorouracil, '''<u>L</u>'''eucovorin (Folinic acid), '''<u>E</u>'''pirubicin, '''<u>C</u>'''arboplatin
 +
<div class="toccolours" style="background-color:#eeeeee">
 
===Regimen {{#subobject:ac72e0|Variant=1}}===
 
===Regimen {{#subobject:ac72e0|Variant=1}}===
 
{| class="wikitable sortable" style="width: 100%; text-align:center;"  
 
{| class="wikitable sortable" style="width: 100%; text-align:center;"  
Line 28: Line 25:
 
|-
 
|-
 
|}
 
|}
 +
<div class="toccolours" style="background-color:#b3e2cd">
 
====Chemotherapy====
 
====Chemotherapy====
−
 
 
*[[Fluorouracil (5-FU)]]
 
*[[Fluorouracil (5-FU)]]
 
*[[Folinic acid (Leucovorin)]]
 
*[[Folinic acid (Leucovorin)]]
 
*[[Epirubicin (Ellence)]]
 
*[[Epirubicin (Ellence)]]
 
*[[Carboplatin (Paraplatin)]]
 
*[[Carboplatin (Paraplatin)]]
−
 
+
</div></div>
 
===References===
 
===References===
−
 
 
#Cantore M, Fiorentini G, Luppi G, Rosati G, Caudana R, Piazza E, Comella G, Ceravolo C, Miserocchi L, Mambrini A, Del Freo A, Zamagni D, Rabbi C, Marangolo M. Gemcitabine versus FLEC regimen given intra-arterially to patients with unresectable pancreatic cancer: a prospective, randomized phase III trial of the Italian Society for Integrated Locoregional Therapy in Oncology. J Chemother. 2004 Dec;16(6):589-94. [https://doi.org/10.1179/joc.2004.16.6.589 link to original article] [https://pubmed.ncbi.nlm.nih.gov/15700852 PubMed]
 
#Cantore M, Fiorentini G, Luppi G, Rosati G, Caudana R, Piazza E, Comella G, Ceravolo C, Miserocchi L, Mambrini A, Del Freo A, Zamagni D, Rabbi C, Marangolo M. Gemcitabine versus FLEC regimen given intra-arterially to patients with unresectable pancreatic cancer: a prospective, randomized phase III trial of the Italian Society for Integrated Locoregional Therapy in Oncology. J Chemother. 2004 Dec;16(6):589-94. [https://doi.org/10.1179/joc.2004.16.6.589 link to original article] [https://pubmed.ncbi.nlm.nih.gov/15700852 PubMed]
−
 
 
=Metastatic disease, first-line=
 
=Metastatic disease, first-line=
 
==PEFG {{#subobject:f0e123|Regimen=1}}==
 
==PEFG {{#subobject:f0e123|Regimen=1}}==
−
 
 
PEFG: '''<u>P</u>'''latinol (Cisplatin), '''<u>E</u>'''pirubicin, '''<u>F</u>'''luorouracil, '''<u>G</u>'''emcitabine
 
PEFG: '''<u>P</u>'''latinol (Cisplatin), '''<u>E</u>'''pirubicin, '''<u>F</u>'''luorouracil, '''<u>G</u>'''emcitabine
 +
<div class="toccolours" style="background-color:#eeeeee">
 
===Regimen {{#subobject:5d6ee0|Variant=1}}===
 
===Regimen {{#subobject:5d6ee0|Variant=1}}===
 
{| class="wikitable sortable" style="width: 100%; text-align:center;"  
 
{| class="wikitable sortable" style="width: 100%; text-align:center;"  
Line 58: Line 53:
 
|-
 
|-
 
|}
 
|}
 +
<div class="toccolours" style="background-color:#b3e2cd">
 
====Chemotherapy====
 
====Chemotherapy====
−
 
 
*[[Cisplatin (Platinol)]] 40 mg/m<sup>2</sup> IV once on day 1
 
*[[Cisplatin (Platinol)]] 40 mg/m<sup>2</sup> IV once on day 1
 
*[[Epirubicin (Ellence)]] 40 mg/m<sup>2</sup> IV once on day 1
 
*[[Epirubicin (Ellence)]] 40 mg/m<sup>2</sup> IV once on day 1
 
*[[Fluorouracil (5-FU)]] 200 mg/m<sup>2</sup>/day IV continuous infusion over 28 days, started on day 1 (total dose per cycle: 5600 mg/m<sup>2</sup>)
 
*[[Fluorouracil (5-FU)]] 200 mg/m<sup>2</sup>/day IV continuous infusion over 28 days, started on day 1 (total dose per cycle: 5600 mg/m<sup>2</sup>)
 
*[[Gemcitabine (Gemzar)]] 600 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1 & 8
 
*[[Gemcitabine (Gemzar)]] 600 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1 & 8
−
 
 
'''28-day cycles'''
 
'''28-day cycles'''
−
 
+
</div></div>
 
===References===
 
===References===
−
 
 
#Reni M, Cordio S, Milandri C, Passoni P, Bonetto E, Oliani C, Luppi G, Nicoletti R, Galli L, Bordonaro R, Passardi A, Zerbi A, Balzano G, Aldrighetti L, Staudacher C, Villa E, Di Carlo V. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. Lancet Oncol. 2005 Jun;6(6):369-76. [https://doi.org/10.1016/S1470-2045(05)70175-3 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/15925814 PubMed]
 
#Reni M, Cordio S, Milandri C, Passoni P, Bonetto E, Oliani C, Luppi G, Nicoletti R, Galli L, Bordonaro R, Passardi A, Zerbi A, Balzano G, Aldrighetti L, Staudacher C, Villa E, Di Carlo V. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. Lancet Oncol. 2005 Jun;6(6):369-76. [https://doi.org/10.1016/S1470-2045(05)70175-3 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/15925814 PubMed]
−
 
 
=Metastatic disease, all lines of therapy=
 
=Metastatic disease, all lines of therapy=
 
==SMF {{#subobject:f7dcb5|Regimen=1}}==
 
==SMF {{#subobject:f7dcb5|Regimen=1}}==
−
 
 
SMF: '''<u>S</u>'''treptozotocin, '''<u>M</u>'''itomycin, 5-'''<u>F</u>'''luorouracil
 
SMF: '''<u>S</u>'''treptozotocin, '''<u>M</u>'''itomycin, 5-'''<u>F</u>'''luorouracil
 +
<div class="toccolours" style="background-color:#eeeeee">
 
===Regimen {{#subobject:251b74|Variant=1}}===
 
===Regimen {{#subobject:251b74|Variant=1}}===
 
{| class="wikitable sortable" style="width: 100%; text-align:center;"  
 
{| class="wikitable sortable" style="width: 100%; text-align:center;"  
Line 90: Line 82:
 
|-
 
|-
 
|}
 
|}
 +
<div class="toccolours" style="background-color:#b3e2cd">
 
====Chemotherapy====
 
====Chemotherapy====
 
*[[Streptozocin (Zanosar)]]
 
*[[Streptozocin (Zanosar)]]
 
*[[Mitomycin (Mutamycin)]]
 
*[[Mitomycin (Mutamycin)]]
 
*[[Fluorouracil (5-FU)]]
 
*[[Fluorouracil (5-FU)]]
−
 
+
</div></div>
 
===References===
 
===References===
 
#Kelsen D, Hudis C, Niedzwiecki D, Dougherty J, Casper E, Botet J, Vinciguerra V, Rosenbluth R. A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma. Cancer. 1991 Sep 1;68(5):965-9. [https://doi.org/10.1002/1097-0142(19910901)68:5%3C965::aid-cncr2820680509%3E3.0.co;2-2 link to original article] [https://pubmed.ncbi.nlm.nih.gov/1833042/ PubMed]
 
#Kelsen D, Hudis C, Niedzwiecki D, Dougherty J, Casper E, Botet J, Vinciguerra V, Rosenbluth R. A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma. Cancer. 1991 Sep 1;68(5):965-9. [https://doi.org/10.1002/1097-0142(19910901)68:5%3C965::aid-cncr2820680509%3E3.0.co;2-2 link to original article] [https://pubmed.ncbi.nlm.nih.gov/1833042/ PubMed]
−
 
 
[[Category:Pancreatic cancer regimens]]
 
[[Category:Pancreatic cancer regimens]]
 
[[Category:Disease-specific pages]]
 
[[Category:Disease-specific pages]]
 
[[Category:Gastrointestinal cancers]]
 
[[Category:Gastrointestinal cancers]]
 
[[Category:Historical regimens]]
 
[[Category:Historical regimens]]

Revision as of 12:05, 1 March 2023

The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the NCCN Guidelines. Is there a regimen missing from this list? See the main pancreatic cancer page for current regimens.

3 regimens on this page
3 variants on this page


Induction therapy for locally advanced disease, unresectable

FLEC

FLEC: Fluorouracil, Leucovorin (Folinic acid), Epirubicin, Carboplatin

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Cantore et al. 2004 1997-2001 Phase 3 (E-esc) Gemcitabine Seems to have superior OS

Chemotherapy

References

  1. Cantore M, Fiorentini G, Luppi G, Rosati G, Caudana R, Piazza E, Comella G, Ceravolo C, Miserocchi L, Mambrini A, Del Freo A, Zamagni D, Rabbi C, Marangolo M. Gemcitabine versus FLEC regimen given intra-arterially to patients with unresectable pancreatic cancer: a prospective, randomized phase III trial of the Italian Society for Integrated Locoregional Therapy in Oncology. J Chemother. 2004 Dec;16(6):589-94. link to original article PubMed

Metastatic disease, first-line

PEFG

PEFG: Platinol (Cisplatin), Epirubicin, Fluorouracil, Gemcitabine

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Reni et al. 2005 2000-2003 Phase 3 (E-esc) Gemcitabine Seems to have superior PFS

Chemotherapy

28-day cycles

References

  1. Reni M, Cordio S, Milandri C, Passoni P, Bonetto E, Oliani C, Luppi G, Nicoletti R, Galli L, Bordonaro R, Passardi A, Zerbi A, Balzano G, Aldrighetti L, Staudacher C, Villa E, Di Carlo V. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. Lancet Oncol. 2005 Jun;6(6):369-76. link to original article contains dosing details in abstract PubMed

Metastatic disease, all lines of therapy

SMF

SMF: Streptozotocin, Mitomycin, 5-Fluorouracil

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Kelsen et al. 1991 1987-1989 Phase 3 (C) CAC Superior OS

Chemotherapy

References

  1. Kelsen D, Hudis C, Niedzwiecki D, Dougherty J, Casper E, Botet J, Vinciguerra V, Rosenbluth R. A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma. Cancer. 1991 Sep 1;68(5):965-9. link to original article PubMed
Retrieved from "https://hemonc.org/w/index.php?title=Pancreatic_cancer_-_historical&oldid=66707"